Biogen reports 38% slowing of Alzheimer’s decline in Phase 2 two‑year data
Biogen announced that its investigational anti‑tau antisense drug diranersen slowed clinical decline by 38% on the CDR‑SB scale after two years in the Phase 2 CELIA study. The 60 mg twice‑yearly regimen produced a 1.09‑point treatment difference versus placebo, with 60 patients on active drug compared with 115 on placebo. The data were presented at the CTAD 2026 conference and the company said the results support moving the asset into a Phase 3 trial.
Why it matters
The company noted that the two‑year benefit strengthens the case for a Phase 3 study and aligns with its Fast Track designation (the company says). Investors may view the data as a positive catalyst for future valuation.
Key facts
- 1Diranersen slowed clinical decline by 38% on CDR‑SB at two years (Week 96) with the 60 mg twice‑yearly regimen, corresponding to a 1.09‑point treatment difference simcoereformer.ca
- 2The 60 mg twice‑yearly regimen was given to 60 participants, while 115 participants were originally randomized to placebo simcoereformer.ca
- 3The data were presented at the Clinical Trials on Alzheimer’s Disease (CTAD) 2026 conference simcoereformer.ca
- 4The FDA granted Fast Track designation for diranersen in 2025 investing.com
Summary written by AlphAI AI Desk from 11 of 11 sources. Not investment advice. Figures are as stated by the linked sources.